To the Editor In a From The JAMA Network article, Drs Perkisas and Vandewoude1 recommended caution in interpretation of our findings in the randomized placebo-controlled trial of ramelteon for prevention of delirium.2 The points that concerned them were (1) a nonsignificant baseline imbalance in the frequency of dementia in the placebo group and the ramelteon group and (2) that we did not clearly indicate to which treatment group 24 patients admitted to intensive care units were allocated. To clarify these points, we performed subanalyses of the original data.
Hatta K, Kishi Y, Wada K. Ramelteon for Delirium in Hospitalized Patients. JAMA. 2015;314(10):1071-1072. doi:10.1001/jama.2015.8522